Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.
about
Modeling of PET data in CNS drug discovery and development.Quantification of fexofenadine in biological matrices: a review of bioanalytical methods.Drug structure-transport relationshipsConcomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumoursQuantifying exploratory low dose compounds in humans with AMS.Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis.Microdosing and drug development: past, present and futureEnhancement of the Oral Bioavailability of Fexofenadine Hydrochloride via Cremophor(®) El-Based Liquisolid Tablets.Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous [(13) C8 ]-evacetrapib as a tracer.AMS method validation for quantitation in pharmacokinetic studies with concomitant extravascular and intravenous administration.Accelerator MS: its role as a frontline bioanalytical technique.Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.Improvement of effect of water-in-oil microemulsion as an oral delivery system for fexofenadine: in vitro and in vivo studies.Approaches to intravenous clinical pharmacokinetics: Recent developments with isotopic microtracers.The application of human phase 0 microdosing trials: A systematic review and perspectives.Continuous Intestinal Absorption Model Based on the Convection-Diffusion Equation.Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transportersThe Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model.Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin.Predicting drug candidate victims of drug-drug interactions, using microdosing.Population pharmacokinetic analysis of fexofenadine in Japanese pediatric patients.Phenylalanine-free taste-masked orodispersible tablets of fexofenadine hydrochloride: development, in vitro evaluation and in vivo estimation of the drug pharmacokinetics in healthy human volunteers.Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors.Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms.Renal Transporter-Mediated Drug-Drug Interactions: Are They Clinically Relevant?Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin.Carbopol-incorporated thermoreversible gel for intranasal drug delivery.
P2860
Q30623699-6CA08FDD-B26C-4BB2-BBE5-9F9002F4120EQ34166009-B5CC24B0-5159-4AB8-BF73-3EBF2AE4944AQ34420259-75D89EF2-23E8-4A15-93D3-C69CB059BFD6Q34571039-F87EFA4C-5560-4E84-A04C-0F2B93D4CC56Q34708648-92D9087C-F7C8-492F-A6F1-DB552B571996Q35846147-12105B9D-2F09-4265-8287-9A5CE7D33A21Q35940544-ABBFB1F4-0D91-48CE-9657-E1683717BE60Q36509478-4C212622-BF25-42C4-86D5-FF3D4947B582Q37340474-30C9E612-E43D-437D-94AB-6109A7E8346CQ37845381-DDA9C4A5-635A-4B16-A8B5-ADCC8A2814ECQ37970117-0E3FE0AC-0639-4C8F-8E43-6B07D958D7ADQ38056878-51107085-B033-4268-A33D-F8524F9EE5E9Q38257856-6F773508-958A-499E-8645-3128F042C9A9Q38527478-5B789C5B-7924-474E-A006-09886DB02837Q38597205-DE07DD5A-E7C6-44BB-AA55-95F12768D496Q38677027-4C16BF2D-91D0-4ED4-97E5-C60864E96304Q39204093-DAF4851E-0B59-4BDE-ADA4-C98312865BE0Q39476375-1E27BEAB-F503-43EF-BA78-D0E01F94DCDEQ43244925-29629809-63E8-44F2-86DA-F693ABF9A23AQ45348533-F7202929-13E8-47BF-99B7-96F011FF2783Q45904644-D7F47A99-AEB8-4AB8-9656-407F0D820432Q46498557-64EC90E9-C64F-4BD9-A331-DED276ADBE9CQ48022375-F6A09CF8-F25C-409C-9558-CE1ED1E2E2CEQ48092928-CF934C90-991B-42D7-A4BD-4F2628FEE3A9Q50871327-4A93446E-A67A-4DD2-8AE7-5861525F4911Q51521654-9A4710E1-B98F-414C-9527-155408F48883Q51659189-C4675A3B-90F3-40FC-A80D-46DAAFCE1B0DQ52334679-B7F798A6-CBB7-42AB-8E83-1276AD64E27FQ52633434-F4E6E1AF-F988-474E-9114-D195D1C73837Q53231081-2979F8BE-EC66-4A49-97CB-A9E72FE64E9C
P2860
Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pharmacokinetics of fexofenadi ...... absolute oral bioavailability.
@ast
Pharmacokinetics of fexofenadi ...... absolute oral bioavailability.
@en
Pharmacokinetics of fexofenadi ...... absolute oral bioavailability.
@nl
type
label
Pharmacokinetics of fexofenadi ...... absolute oral bioavailability.
@ast
Pharmacokinetics of fexofenadi ...... absolute oral bioavailability.
@en
Pharmacokinetics of fexofenadi ...... absolute oral bioavailability.
@nl
prefLabel
Pharmacokinetics of fexofenadi ...... absolute oral bioavailability.
@ast
Pharmacokinetics of fexofenadi ...... absolute oral bioavailability.
@en
Pharmacokinetics of fexofenadi ...... absolute oral bioavailability.
@nl
P2093
P1476
Pharmacokinetics of fexofenadi ...... absolute oral bioavailability.
@en
P2093
Berend Oosterhuis
Brian Houston
Charlotte Gesson
Colin Garner
Graham Lappin
Malcolm Rowland
Ole J Bjerrum
Richard John Weaver
Roeline Jochemsen
Yoko Shishikura
P304
P356
10.1016/J.EJPS.2010.03.009
P407
P577
2010-03-20T00:00:00Z